Full course description

About this Course

Precision Medicine For Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Exploring Somatic Cancer Panel Testing, participants will learn about large somatic cancer panels, which test for dozens or hundreds of variants that may be driving cancer growth and suggest therapeutics targeted to the variants that are identified. When should these panels be used? And which patients are good candidates? Learn about benefits, limitations, and challenges of using large somatic cancer panels using the five parts of this module: overview information via an animated video; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

CME Disclosures

Release Date: December 20, 2016 
Expiration Date: December 20, 2019

Objectives
Upon completion of this educational activity, the learner will be able to:

  • Identify the types of clinical information that can be gained from large somatic cancer panels.
  • Determine how large somatic cancer panel results could be applied to patient care.

Target Audience
This activity is designed to meet the educational needs of practicing physicians who provide oncology care.

Statement of Need
Genetic technology is rapidly expanding, often too quickly for physicians and other health professionals to become familiar with new technologies before their patients inquire about them, and too quickly for adequate evidence regarding the clinical utility of the technologies to be produced. This educational module will assist physicians and health professionals to determine when somatic cancer panel testing is appropriate for their patients and how to interpret the results of such testing.

Statement of Competency
This activity is designed to address the following ABMS/ACGME competencies: patient care, medical knowledge, and interpersonal and communication skills.

Accreditation Statement
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The American Medical Association designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming Your CME Credit
In order to claim AMA PRA Category 1 Credit™, you must: 1) answer the pre-assessment questions, 2) work through the module in its entirety, 3) successfully complete the post-assessment by answering 2 out of 3 questions correctly and 4) complete the evaluation.

Planning Committee

  • Barry D. Dickinson, PhD, CME Program Committee, AMA
  • Abdallah Elias, MD, Department of Medical Genetics, Shodair Children's Hospital
  • Jeanette McCarthy, MPH, PhD, Visiting Associate Professor, Division of Medical Genetics, UCSF School of Medicine
  • Laura Nicholson, MD, Co-Director of Education, Scripps Translational Science Institute
  • James O'Leary, MBA, Chief innovation Officer, Genetic Alliance
  • Janet K. Williams, PhD, RN, FAAN, Professor of Nursing, Chair of Behavioral and Social Science Research, University of Iowa

Faculty

  • Barry D. Dickinson, PhD, CME Program Committee, AMA (Content Reviewer)
  • Emily Edelman, MS, CGC, Associate Director, Clinical and Continuing Education, The Jackson Laboratory (Author)
  • Abdallah Elias, MD, Department of Medical Genetics, Shodair Children's Hospital (Content Reviewer)
  • Marilyn J. Heine, MD, Hematologist/Oncologists, Regional Hematology Oncology Associates (Content Consultant)
  • Therese Ingram Nissen, MA, Senior Instructional Designer/Technologist, The Jackson Laboratory (Author)
  • Katie Johansen Taber, PhD, Principal Policy Analyst, Science and Biotechnology, AMA (Author)
  • Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants (Content Consultant)
  • Laura Nicholson, MD, Co-Director of Education, Scripps Translational Science Institute (Author)
  • James O'Leary, MBA, Chief innovation Officer, Genetic Alliance (Content Reviewer)
  • Kate Reed, MPH, ScM, CGC, Director, Clinical and Continuing Education, The Jackson Laboratory (Author)
  • Suzanna Schott, ScM, CGC, Medical Writer, The Jackson Laboratory (Author)

Disclosure Statement
In order to assure the highest quality of certified CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty, planners and members of the AMA CME Program Committee disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. The following disclosures are provided:

  • Barbara L. McAneny, MD, CEO of Innovative Oncology Business Solutions, and CEO or New Mexico Hematology Oncology Consultants Ltd
  • Jeanette McCarthy, PhD, MPH, Consultant to Big Science Media, Omicia, and Precision Medicine Advisors
  • Suzanna Schott, ScM, CGC, Stockholder of Merck, Amgen, and Teva
  • Janet K. Williams, PhD, RN, FAAN, Stockholder of Pfizer

No other planners or faculty have relevant financial relationships to disclose.

References

Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. Am Soc Clin Oncol Educ Book. 2015:e175-82. http://www.ncbi.nlm.nih.gov/pubmed/25993170

Gingras I, Sonnenblick A, de Azambuja E, et al. The current use and attitudes towards tumor genome sequencing in breast cancer. Sci Rep. 2016. 6:22517 http://www.ncbi.nlm.nih.gov/pubmed/26931736

Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May. 32(13):1317-23. http://www.ncbi.nlm.nih.gov/pubmed/24663044

Gray SW, Park ER, Najita J, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016. 18(10):1011-9. http://www.ncbi.nlm.nih.gov/pubmed/26866579

Le Tourneau C, Kamal M, Tsimberidou AM, et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst. 2015. 108(4). http://www.ncbi.nlm.nih.gov/pubmed/26598514

Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res. 2012. 22(11):2101-8. http://www.ncbi.nlm.nih.gov/pubmed/23019146

Marrone M, Filipski KK, Gillanders EM, Schully SD, Freedman AN. Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. PLoS Curr. 2014. 6. http://www.ncbi.nlm.nih.gov/pubmed/24904755

National Comprehensive Cancer Center. Guidelines for Treatment of Cancer by Site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014. 94(2):129-37. http://www.ncbi.nlm.nih.gov/pubmed/24378644

Subbiah V, Kurzrock R. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016. 2(6):719-20. http://www.ncbi.nlm.nih.gov/pubmed/27078832

Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. N Engl J Med. 2016. 375(13):1289-94. http://www.ncbi.nlm.nih.gov/pubmed/27682039

West HJ. No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data. JAMA Oncol. 2016. ;2(6):717-8. http://www.ncbi.nlm.nih.gov/pubmed/27078630

Hardware/software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 

As of June 4, 2016, we support the following versions of Flash and popular web browsers:

Operating Systems

  • Windows 7 and newer
  • Mac OSX 10.6 and newer
  • Linux - chromeOS

Mobile Operating System Native App Support

  • iOS 7 and newer
  • Android 4.2 and newer
Should you have questions regarding the content of the activity or if you need technical support, please email Clinical and Continuing Education at the Jackson Laboratory.